Corrigendum: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

Front Endocrinol (Lausanne). 2021 Dec 28;12:830469. doi: 10.3389/fendo.2021.830469. eCollection 2021.


[This corrects the article DOI: 10.3389/fendo.2021.779365.].

Keywords: IGF-2; PEG-rhGH; PEGylated recombinant human growth hormone; children; growth hormone deficiency.

Publication types

  • Published Erratum